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Introduction
Familial Mediterranean Fever (FMF), the most common
form of the hereditary autoinflammatory disorders, is
characterized by recurrent attacks of fever along with
serosal or synovial inflammation lasting usually 12 to 72
hours. FMF is associated with impaired functional abil-
ity, and the persistent disabling features and chronic
pain, emotional and physical limitations can have a
negative impact on the health-related quality of life
(QoL) of the patients.
There is no established treatment available for those
resistant or intolerant to standard of care colchicine
treatment. Interleukin-1 (IL-1) plays a pivotal role in the
pathogenesis of crFMF. Canakinumab, a fully human,
selective, anti-IL-1b monoclonal antibody, binds to IL-1b
and inactivates its signalling activity. Gul et al. have
described the efficacy and safety of canakinumab in
adults with colchicine resistant (cr) FMF in a local pivotal
phase II trial. Here, we report the effect of canakinumab
treatment on QoL measured by SF-36 Questionnaire.
Objectives
This study aimed to show the effects of canakinumab
treatment on quality of life by 8 sub-items of SF-36 as well
as to see the correlation between the Physician Global
Assessments (PGA) and SF-36 scores.
Methods
9 crFMF patients with ≥1 attack/month in the preceding
3-months despite the highest tolerated colchicine dose
entered the study. Canakinumab injections were adminis-
tered at Day 1, Day 29 and Day 57. Changes in the quality
of life was recorded in 9 subjects by using SF-36 at Day 1,
8, 29, 57, 86, 115 and the end of the study.
Results
In all 8 items (physical functioning, role limitations due
to emotional/physical health, energy, emotional-well
being, body pain, social functioning and general health)
of SF-36 scores improved dramatically with canakinumab
treatment, starting from 1st day. However the differences
in emotional well-being and role limitations due to emo-
tional problems scores couldn’t reach the statistical sig-
nificance. All scores are showed in tables below. Also
there was a strong negative correlation between Physician
Global Assessment (PGA) and Physical Component
Score (R-sq: -0,793). A weaker correlation observed
between Mental Component Score and Physical Global
Assessment (R-sq: -0,540).
Conclusion
Canakinumab treatment in cr-FMF patients resulted in a
rapid improvement in QoL measures. Also these improve-
ments sustained during the withdrawal period. PGA scores
appear to be in compliance with the Physical and Mental
Component scores of the SF-36 questionnaires. A stronger
correlation was observed for the Physical Component
Score.
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